231 Results for "

bispecific

" in MedChemExpress (MCE) Product Catalog:
Products (231)

231 Results for "bispecific" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P9977
CAS No.: 2171511-58-1
Synonyms: JNJ-61186372

Target:  

EGFR

Research Areas:  

Cancer

Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9963
CAS No.: 853426-35-4
Synonyms: bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO

Target:  

CD19

Research Areas:  

Cancer

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99575
CAS No.: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Research Areas:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99931
CAS No.: 2134641-34-0
Synonyms: GEN3013
Target:  

CD3 CD20

Research Areas:  

Cancer

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99011
CAS No.: 1855925-27-7
Synonyms: RG-7802; RO-6958688; CEA-TCB

Target:  

CD3

Research Areas:  

Cancer

Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99024
CAS No.: 2229047-91-8
Synonyms: RO7082859; RG-6026

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99033
CAS No.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99380
CAS No.: 2169946-15-8
Synonyms: ZW 25; ZW-49 Antibody

Target:  

EGFR

Research Areas:  

Cancer

Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99592
CAS No.: 1005198-65-1
Synonyms: AMG 110

Target:  

CD3

Research Areas:  

Cancer

Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99507
CAS No.: 1969309-56-5
Synonyms: MCLA-128; PB4188; R040517

Target:  

EGFR

Research Areas:  

Cancer

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99394
CAS No.: 2226212-40-2
Synonyms: JNJ-64407564

Target:  

CD3

Research Areas:  

Cancer

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99802
CAS No.: 1442657-12-6
Synonyms: BAY 2010112; AMG 212; MT112

Target:  

CD3

Research Areas:  

Cancer

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135140
CAS No.: 1345955-28-3
Purity:  98.02%
Research Areas:  

Others

Methyltetrazine-amine, a tetrazine compound, is used for the site-specific dual functionalization of the resulting bioconjugates .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99350
CAS No.: 2413817-97-5
Synonyms: AMG 910; Anti-Human CD3xClaudin18 2

Target:  

CD3

Research Areas:  

Cancer

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135140A
CAS No.: 1596117-29-1
Purity:  99.74%
Research Areas:  

Others

Methyltetrazine-Amine hydrochloride is a tetrazine compound. Methyltetrazine-Amine hydrochloride can be used for the site-specific dual functionalization of the resulting bioconjugates. Methyltetrazine-Amine hydrochloride can be added during protein precipitation in experiments using trans-cyclooctene .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99437
CAS No.: 2367012-88-0
Synonyms: KN-026

Target:  

EGFR

Research Areas:  

Cancer

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99814
CAS No.: 2250292-39-6
Synonyms: AMG-701

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99762
CAS No.: 2069959-72-2
Synonyms: MGD009

Target:  

CD3

Research Areas:  

Cancer

Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99675
CAS No.: 2428381-53-5
Synonyms: AK112

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
loading...
    loading...